Nektar Therapeutics Shareholder Claims Notification
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy NKTR?
Source: PRnewswire
- Shareholder Claim Opportunity: Investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, may be entitled to recover losses, particularly after the company's stock fell 7.77% due to poor trial results.
- Trial Result Impact: On December 16, 2025, Nektar's shares dropped by $4.14 to close at $49.16 after it was revealed that four ineligible patients were enrolled in the REZOLVE-AA study, severely impacting investor confidence.
- Management Concealment Issues: The lawsuit alleges that management repeatedly claimed rigorous trial standards over ten months while concealing violations of those standards, leading to a decline in investor trust in the company.
- Claim Deadline: Investors must submit claims by May 5, 2026, raising questions about the fairness and efficiency of the market due to the failure to timely disclose material developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 68.660
Low
102.00
Averages
123.43
High
165.00
Current: 68.660
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rezpegaldesleukin Shows Significant Efficacy at Dermatology Conference
- Clinical Trial Results: At the 2026 American Academy of Dermatology Annual Meeting, Nektar Therapeutics presented data from the Phase 2b REZOLVE-AD study involving 393 patients with moderate-to-severe atopic dermatitis, demonstrating significant improvements in EASI scores over 16 weeks, indicating potential changes to treatment standards across varying disease severities.
- Efficacy Comparison: Rezpegaldesleukin showed significant differences in EASI-75 and EASI-90 response rates compared to placebo, further proving its consistent efficacy in severe patients, which may provide treatment options for a broader patient population and enhance market competitiveness.
- New Research Presentation: Nektar also showcased the Phase 2b REZOLVE-AA study results for severe alopecia areata, revealing a 28.2% reduction in SALT scores at 36 weeks in the high-dose group, significantly outperforming the placebo group, highlighting the drug's potential across various immune-mediated diseases.
- Future Development Plans: Following the positive outcomes from the REZOLVE-AD study, Nektar plans to initiate the Phase 3 ZENITH-AD program in the second quarter of 2026, further validating the efficacy of Rezpegaldesleukin in moderate-to-severe atopic dermatitis patients, signaling the company's strategic expansion in this field.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Nektar class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses once the true information was disclosed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this legal domain.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Nektar Therapeutics investors of a class action lawsuit for those who purchased securities between February 26, 2026, and December 12, 2025, with a deadline of May 5, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Stock Price Impact: Nektar's stock price fell nearly 8% on December 16, 2025, following disappointing topline results from its Phase 2b REZOLVE-AA trial, which narrowly missed statistical significance, undermining investor confidence and affecting the company's future market performance.
- Trial Integrity Concerns: The lawsuit alleges that Nektar failed to disclose that enrollment did not adhere to applicable instructions and protocol standards, likely leading to significant negative impacts on the study's findings, thus misleading investors about the trial's prospects.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations to help investors pursue claims for losses caused by corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors, showcasing their strength in such cases.
See More
Faruqi & Faruqi Encourages Nektar Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics, particularly for investors who purchased securities between February 26, 2025, and December 15, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a strong commitment to client service.
- Class Action Deadline: The firm reminds investors that the deadline to seek lead plaintiff status in the federal securities class action against Nektar is May 5, 2026, emphasizing the importance of timely action for affected investors.
- Role of Securities Law Firm: As a leading national securities law firm, Faruq & Faruqi's investigation indicates significant legal scrutiny on Nektar, which may impact its stock price and investor confidence, reflecting market concerns regarding the company's compliance.
See More
Reminder of Class Action Lawsuit for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, to apply as lead plaintiffs by May 5, 2026, to represent other members in the class action lawsuit.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors seeking compensation.
- Lawsuit Background: The lawsuit alleges that defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, which likely compromised the trial's integrity and resulted in investor losses when the truth was revealed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this legal domain.
See More
Rezpegaldesleukin Shows Significant Efficacy in Atopic Dermatitis and Alopecia Areata Studies
- Eczema Treatment Success: In the Phase 2b REZOLVE-AD study involving 393 patients with moderate-to-severe atopic dermatitis, Rezpegaldesleukin demonstrated significant improvements in EASI scores over 16 weeks, indicating its potential to redefine treatment standards across varying disease severities.
- Alopecia Improvement: In patients with severe-to-very-severe alopecia areata, Rezpegaldesleukin achieved a 28.2% reduction in SALT scores at 36 weeks compared to 11.2% in the placebo group, highlighting its broader applicability in autoimmune conditions.
- Clinical Trial Expansion: Following positive results from the REZOLVE-AD study, Nektar plans to initiate the Phase 3 ZENITH-AD program in the second quarter of 2026, aiming to further validate Rezpegaldesleukin's efficacy in moderate-to-severe atopic dermatitis patients, signaling strong market potential ahead.
- FDA Fast Track Designation: Rezpegaldesleukin has received Fast Track designation from the FDA for both moderate-to-severe atopic dermatitis and severe alopecia areata, indicating promising therapeutic prospects that could expedite its market entry and enhance the company's competitive edge.
See More
Rezpegaldesleukin Shows Significant Efficacy at Dermatology Conference
- Clinical Trial Results: At the 2026 American Academy of Dermatology Annual Meeting, Nektar Therapeutics presented data from the Phase 2b REZOLVE-AD study involving 393 patients with moderate-to-severe atopic dermatitis, demonstrating significant improvements in EASI scores over 16 weeks, indicating potential changes to treatment standards across varying disease severities.
- Efficacy Comparison: Rezpegaldesleukin showed significant differences in EASI-75 and EASI-90 response rates compared to placebo, further proving its consistent efficacy in severe patients, which may provide treatment options for a broader patient population and enhance market competitiveness.
- New Research Presentation: Nektar also showcased the Phase 2b REZOLVE-AA study results for severe alopecia areata, revealing a 28.2% reduction in SALT scores at 36 weeks in the high-dose group, significantly outperforming the placebo group, highlighting the drug's potential across various immune-mediated diseases.
- Future Development Plans: Following the positive outcomes from the REZOLVE-AD study, Nektar plans to initiate the Phase 3 ZENITH-AD program in the second quarter of 2026, further validating the efficacy of Rezpegaldesleukin in moderate-to-severe atopic dermatitis patients, signaling the company's strategic expansion in this field.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Nektar class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses once the true information was disclosed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this legal domain.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Nektar Therapeutics investors of a class action lawsuit for those who purchased securities between February 26, 2026, and December 12, 2025, with a deadline of May 5, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Stock Price Impact: Nektar's stock price fell nearly 8% on December 16, 2025, following disappointing topline results from its Phase 2b REZOLVE-AA trial, which narrowly missed statistical significance, undermining investor confidence and affecting the company's future market performance.
- Trial Integrity Concerns: The lawsuit alleges that Nektar failed to disclose that enrollment did not adhere to applicable instructions and protocol standards, likely leading to significant negative impacts on the study's findings, thus misleading investors about the trial's prospects.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations to help investors pursue claims for losses caused by corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors, showcasing their strength in such cases.
See More
Faruqi & Faruqi Encourages Nektar Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics, particularly for investors who purchased securities between February 26, 2025, and December 15, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a strong commitment to client service.
- Class Action Deadline: The firm reminds investors that the deadline to seek lead plaintiff status in the federal securities class action against Nektar is May 5, 2026, emphasizing the importance of timely action for affected investors.
- Role of Securities Law Firm: As a leading national securities law firm, Faruq & Faruqi's investigation indicates significant legal scrutiny on Nektar, which may impact its stock price and investor confidence, reflecting market concerns regarding the company's compliance.
See More
Reminder of Class Action Lawsuit for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, to apply as lead plaintiffs by May 5, 2026, to represent other members in the class action lawsuit.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors seeking compensation.
- Lawsuit Background: The lawsuit alleges that defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, which likely compromised the trial's integrity and resulted in investor losses when the truth was revealed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this legal domain.
See More
Rezpegaldesleukin Shows Significant Efficacy in Atopic Dermatitis and Alopecia Areata Studies
- Eczema Treatment Success: In the Phase 2b REZOLVE-AD study involving 393 patients with moderate-to-severe atopic dermatitis, Rezpegaldesleukin demonstrated significant improvements in EASI scores over 16 weeks, indicating its potential to redefine treatment standards across varying disease severities.
- Alopecia Improvement: In patients with severe-to-very-severe alopecia areata, Rezpegaldesleukin achieved a 28.2% reduction in SALT scores at 36 weeks compared to 11.2% in the placebo group, highlighting its broader applicability in autoimmune conditions.
- Clinical Trial Expansion: Following positive results from the REZOLVE-AD study, Nektar plans to initiate the Phase 3 ZENITH-AD program in the second quarter of 2026, aiming to further validate Rezpegaldesleukin's efficacy in moderate-to-severe atopic dermatitis patients, signaling strong market potential ahead.
- FDA Fast Track Designation: Rezpegaldesleukin has received Fast Track designation from the FDA for both moderate-to-severe atopic dermatitis and severe alopecia areata, indicating promising therapeutic prospects that could expedite its market entry and enhance the company's competitive edge.
See More
